RhumbLine Advisers’s Eterna Therapeutics ERNA Stock Holding History

RhumbLine Advisers’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3	Closed	-$52K	–	3140
2022 Q1	$52K	Buy	3 +1	+50%	+$19K	﹤0.01%	2970
2021 Q4	$74K	Hold	2	–	–	﹤0.01%	2963
2021 Q3	$165K	Hold	2	–	–	﹤0.01%	2939
2021 Q2	$263K	Buy	+2	New	+$288K	﹤0.01%	2833

Other funds holding ERNA

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RhumbLine Advisers's ERNA Position: Q2 2022 in Review

RhumbLine Advisers sold out of Eterna Therapeutics (ERNA) in Q2 2022, closing a stake of 3 shares — an estimated $52K sold.

RhumbLine Advisers first reported a position in ERNA in Q2 2021 and held it in 4 quarters. The position peaked at $263K in Q2 2021. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

RhumbLine Advisers reported no remaining Eterna Therapeutics position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 3 Eterna Therapeutics shares in Q2 2022, an estimated $52K.
RhumbLine Advisers first reported a position in Eterna Therapeutics in Q2 2021 and held it in 4 quarters.
RhumbLine Advisers's Eterna Therapeutics position peaked at $263K in Q2 2021.
34 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.